SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* E&Investment, Inc. (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC 177 HUNTINGTON AVENUE, SUITE 1700 (Street) BOSTON MA 02115 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/30/2019	3. Issuer Name and Ticker or Trading Symbol NeuroBo Pharmaceuticals, Inc. [ NRBO ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 01/09/2020
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,335,800	I	Held by The E&Healthcare Investment Fund II(1)(4)
Common Stock	1,121,190	I	Held by The E&Healthcare Investment Fund No. 6(2)(4)
Common Stock	1,864,799	I	Held by The E&Healthcare Investment Fund No. 7(3)(4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* E&Investment, Inc. (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC 177 HUNTINGTON AVENUE, SUITE 1700 (Street) BOSTON MA 02115 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* E&Healthcare Investment Fund II (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC 177 HUNTINGTON AVENUE, SUITE 1700 (Street) BOSTON MA 02115 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* E&Healthcare Investment Fund No.7 (Last) (First) (Middle) C/O NEUROBO PHARMACEUTICALS, INC 177 HUNTINGTON AVENUE, SUITE 1700 (Street) BOSTON MA 02115 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. These shares are owned directly by The E&Healthcare Investment Fund II, a 10% owner of the Issuer, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund II.

2. These shares are owned directly by The E&Healthcare Investment Fund No. 6, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund No. 6

3. These shares are owned directly by The E&Healthcare Investment Fund No.7, a 10% owner of the Issuer, and indirectly by E&Investment, Inc., as sole general partner of The E&Healthcare Investment Fund No.7.

4. E&Investment, Inc. disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Remarks:

This Form 3 is being amended to add The E&Healthcare Investment Fund II and The E&Healthcare Investment Fund No.7 as Reporting Persons.

	/s/ E&Investment, Inc., By: Na Yeon Kim, CEO	01/10/2020
	/s/ The E&Healthcare Investment Fund II By: Na Yeon Kim, Representative Director	01/10/2020
	/s/ The E&Healthcare Investment Fund No.7 By: Na Yeon Kim, Representative Director	01/10/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.